Latest Insights VIEW MORE
Consumer Cyclical
Biotechnology, Clinical Trials, FDA, IND,
07 . 18 . 2019
Positive Interim Results from Clinical Trial Offers Hope to Patients with Duchenne Muscular Dystrophy (DMD)
Consumer Cyclical
Biotechnology, Clinical Trials, Industry, Trending,
07 . 16 . 2019
Targeted Immunotherapy – Revigorating The Treatment Of Prostate Cancer
Related Tickers
BABA Alibaba Group Holding Limited
122.05 -1.36%
MELI MercadoLibre, Inc.
1,715.52 -0.20%
SE Sea Limited
82.28 +0.15%
JD JD.com, Inc.
28.46 -1.42%
CPNG Coupang, Inc.
18.95 +0.16%
DASH DoorDash, Inc.
156.45 +3.95%
CHWY Chewy, Inc.
26.87 +0.94%
PDD PDD Holdings Inc.
100.87 -0.89%
EBAY eBay Inc.
94.14 +1.08%
9988.HK Alibaba Group Holding Limited
118.500 -3.42%
Recent Events
August 27, 2025 at 12:00 AM UTC
N-PX: Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX
Performance
Performance Overview: AMZN
Trailing total returns as of 4/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
AMZN
9.12%
S&P 500 (^GSPC)
3.84%
1-Year Return
AMZN
7.02%
S&P 500 (^GSPC)
16.08%
3-Year Return
AMZN
103.09%
S&P 500 (^GSPC)
60.19%
5-Year Return
AMZN
32.72%
S&P 500 (^GSPC)
63.75%
Financials
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 716,924,000 | 637,959,000 | 574,785,000 | 513,983,000 | 469,822,000 |
| Cost of Goods | 356,414,000 | 326,288,000 | 304,739,000 | 288,831,000 | 272,344,000 |
| Gross Profit | 360,510,000 | 311,671,000 | 270,046,000 | 225,152,000 | 197,478,000 |
| Operating Expenses | 280,535,000 | 243,078,000 | 233,194,000 | 212,904,000 | 172,599,000 |
| Operating Income | 79,975,000 | 68,593,000 | 36,852,000 | 12,248,000 | 24,879,000 |
| Interest Expense | 2,274,000 | 2,406,000 | 3,182,000 | 2,367,000 | 1,809,000 |
| Other Income | 19,056,000 | 2,326,000 | 3,875,000 | -15,820,000 | 15,085,000 |
| Pre-tax Income | 96,757,000 | 68,513,000 | 37,545,000 | -5,939,000 | 38,155,000 |
| Income Tax | 19,087,000 | 9,265,000 | 7,120,000 | -3,217,000 | 4,791,000 |
| Net Income Continuous | 77,670,000 | 59,248,000 | 30,425,000 | -2,722,000 | 33,364,000 |
| Net Income | $77,670,000 | $59,248,000 | $30,425,000 | $-2,722,000 | $33,364,000 |
| EPS Basic Total Ops | 7.29 | 5.66 | 2.95 | -0.27 | 3.30 |
| EPS Basic Continuous Ops | 7.29 | 5.66 | 2.95 | -0.27 | 3.30 |
| EPS Diluted Total Ops | 7.17 | 5.53 | 2.90 | -0.27 | 3.24 |
| EPS Diluted Continuous Ops | 7.17 | 5.53 | 2.90 | -0.27 | 3.24 |
| EPS Diluted Before Non-Recurring Items | 7.17 | 5.53 | 2.84 | 0.71 | 3.24 |
| EBITDA(a) | $145,731,000 | $121,388,000 | $85,515,000 | $54,169,000 | $59,312,000 |
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 213,386,000 | 180,169,000 | 167,702,000 | 155,667,000 | 187,792,000 |
| Cost of Goods | 109,959,000 | 88,670,000 | 80,809,000 | 76,976,000 | 98,893,000 |
| Gross Profit | 103,427,000 | 91,499,000 | 86,893,000 | 78,691,000 | 88,899,000 |
| Operating Expenses | 78,450,000 | 74,077,000 | 67,722,000 | 60,286,000 | 67,696,000 |
| Operating Income | 24,977,000 | 17,422,000 | 19,171,000 | 18,405,000 | 21,203,000 |
| Interest Expense | 679,000 | 538,000 | 516,000 | 541,000 | 570,000 |
| Other Income | 1,840,000 | 11,213,000 | 2,187,000 | 3,816,000 | 1,696,000 |
| Pre-tax Income | 26,138,000 | 28,097,000 | 20,842,000 | 21,680,000 | 22,329,000 |
| Income Tax | 4,946,000 | 6,910,000 | 2,678,000 | 4,553,000 | 2,325,000 |
| Net Income Continuous | 21,192,000 | 21,187,000 | 18,164,000 | 17,127,000 | 20,004,000 |
| Net Income | $21,192,000 | $21,187,000 | $18,164,000 | $17,127,000 | $20,004,000 |
| EPS Basic Total Ops | 1.98 | 1.98 | 1.71 | 1.62 | 1.91 |
| EPS Basic Continuous Ops | 1.98 | 1.98 | 1.71 | 1.62 | 1.90 |
| EPS Diluted Total Ops | 1.95 | 1.95 | 1.68 | 1.59 | 1.86 |
| EPS Diluted Continuous Ops | 1.95 | 1.95 | 1.68 | 1.59 | 1.86 |
| EPS Diluted Before Non-Recurring Items | 1.95 | 1.95 | 1.68 | 1.59 | 1.86 |
| EBITDA(a) | $44,448,000 | $34,218,000 | $34,398,000 | $32,667,000 | $36,834,000 |
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 86,810,000 | 78,779,000 | 73,387,000 | 53,888,000 | 36,220,000 |
| Marketable Securities | 36,219,000 | 22,423,000 | 13,393,000 | 16,138,000 | 59,829,000 |
| Receivables | 67,729,000 | 55,451,000 | 52,253,000 | 42,360,000 | 32,891,000 |
| Inventories | 38,325,000 | 34,214,000 | 33,318,000 | 34,405,000 | 32,640,000 |
| TOTAL | $229,083,000 | $190,867,000 | $172,351,000 | $146,791,000 | $161,580,000 |
| Non-Current Assets | |||||
| PPE Net | 357,025,000 | 252,665,000 | 204,177,000 | 186,715,000 | 160,281,000 |
| Intangibles | 23,273,000 | 23,074,000 | 22,789,000 | 20,288,000 | 15,371,000 |
| Other Non-Current Assets | 208,661,000 | 158,288,000 | 128,537,000 | 108,881,000 | 83,317,000 |
| TOTAL | $588,959,000 | $434,027,000 | $355,503,000 | $315,884,000 | $258,969,000 |
| Total Assets | $818,042,000 | $624,894,000 | $527,854,000 | $462,675,000 | $420,549,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 121,909,000 | 94,363,000 | 84,981,000 | 79,600,000 | 78,664,000 |
| Accrued Expenses | 75,520,000 | 66,965,000 | 64,709,000 | 62,566,000 | 51,775,000 |
| Other current liabilities | 20,576,000 | 18,103,000 | 15,227,000 | 13,227,000 | 11,827,000 |
| TOTAL | $218,005,000 | $179,431,000 | $164,917,000 | $155,393,000 | $142,266,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 65,648,000 | 52,623,000 | 58,314,000 | 67,150,000 | 48,744,000 |
| Other Non-Current Liabilities | 123,324,000 | 106,870,000 | 102,748,000 | 94,089,000 | 91,294,000 |
| TOTAL | $188,972,000 | $159,493,000 | $161,062,000 | $161,239,000 | $140,038,000 |
| Total Liabilities | $406,977,000 | $338,924,000 | $325,979,000 | $316,632,000 | $282,304,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 10,734,920 | 10,597,730 | 10,387,380 | 10,247,260 | 10,176,890 |
| Common Shares | 112,000 | 111,000 | 109,000 | 108,000 | 106,000 |
| Retained earnings | 250,536,000 | 172,866,000 | 113,618,000 | 83,193,000 | 85,915,000 |
| Other shareholders' equity | 28,230,000 | -34,000 | -3,040,000 | -4,487,000 | -1,376,000 |
| TOTAL | $411,065,000 | $285,970,000 | $201,875,000 | $146,043,000 | $138,245,000 |
| Total Liabilities And Equity | $818,042,000 | $624,894,000 | $527,854,000 | $462,675,000 | $420,549,000 |
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 86,810,000 | 66,922,000 | 57,741,000 | 66,207,000 | 78,779,000 |
| Marketable Securities | 36,219,000 | 27,275,000 | 35,439,000 | 28,358,000 | 22,423,000 |
| Receivables | 67,729,000 | 61,175,000 | 57,415,000 | 54,216,000 | 55,451,000 |
| Inventories | 38,325,000 | 41,494,000 | 40,825,000 | 35,864,000 | 34,214,000 |
| TOTAL | $229,083,000 | $196,866,000 | $191,420,000 | $184,645,000 | $190,867,000 |
| Non-Current Assets | |||||
| PPE Net | 357,025,000 | 324,435,000 | 297,616,000 | 272,781,000 | 252,665,000 |
| Intangibles | 23,273,000 | 23,260,000 | 23,155,000 | 23,089,000 | 23,074,000 |
| Other Non-Current Assets | 208,661,000 | 183,360,000 | 169,979,000 | 162,741,000 | 158,288,000 |
| TOTAL | $588,959,000 | $531,055,000 | $490,750,000 | $458,611,000 | $434,027,000 |
| Total Assets | $818,042,000 | $727,921,000 | $682,170,000 | $643,256,000 | $624,894,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 121,909,000 | 106,032,000 | 98,285,000 | 89,241,000 | 94,363,000 |
| Accrued Expenses | 75,520,000 | 68,051,000 | 66,974,000 | 66,331,000 | 66,965,000 |
| Other current liabilities | 20,576,000 | 21,113,000 | 21,662,000 | 20,599,000 | 18,103,000 |
| TOTAL | $218,005,000 | $195,196,000 | $186,921,000 | $176,171,000 | $179,431,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 65,648,000 | 50,742,000 | 50,718,000 | 53,374,000 | 52,623,000 |
| Other Non-Current Liabilities | 123,324,000 | 112,352,000 | 110,756,000 | 107,844,000 | 106,870,000 |
| TOTAL | $188,972,000 | $163,094,000 | $161,474,000 | $161,218,000 | $159,493,000 |
| Total Liabilities | $406,977,000 | $358,290,000 | $348,395,000 | $337,389,000 | $338,924,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 10,734,920 | 10,690,220 | 10,664,910 | 10,616,350 | 10,597,730 |
| Common Shares | 112,000 | 112,000 | 112,000 | 111,000 | 111,000 |
| Retained earnings | 250,536,000 | 229,344,000 | 208,157,000 | 189,993,000 | 172,866,000 |
| Other shareholders' equity | 28,230,000 | 12,333,000 | 2,420,000 | -914,000 | -34,000 |
| TOTAL | $411,065,000 | $369,631,000 | $333,775,000 | $305,867,000 | $285,970,000 |
| Total Liabilities And Equity | $818,042,000 | $727,921,000 | $682,170,000 | $643,256,000 | $624,894,000 |
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 77,670,000 | 59,248,000 | 30,425,000 | -2,722,000 | 33,364,000 |
| Depreciation Amortization | 65,756,000 | 52,795,000 | 48,663,000 | 41,921,000 | 34,433,000 |
| Income taxes - deferred | 11,470,000 | -4,648,000 | -5,876,000 | -8,148,000 | -310,000 |
| Accounts receivable | -7,333,000 | -3,249,000 | -8,348,000 | -8,622,000 | -9,145,000 |
| Accounts payable and accrued liabilities | 11,231,000 | 2,972,000 | 5,473,000 | 2,945,000 | 3,602,000 |
| Other Working Capital | -19,969,000 | -15,541,000 | -11,541,000 | -20,886,000 | -19,611,000 |
| Other Operating Activity | 689,000 | 24,300,000 | 26,150,000 | 42,264,000 | 3,994,000 |
| Operating Cash Flow | $139,514,000 | $115,877,000 | $84,946,000 | $46,752,000 | $46,327,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -128,320,000 | -77,658,000 | -48,133,000 | -58,321,000 | -55,396,000 |
| Net Acquisitions | -3,841,000 | -7,082,000 | -5,839,000 | -8,316,000 | -1,985,000 |
| Purchase Of Investment | -54,770,000 | -26,005,000 | -1,488,000 | -2,565,000 | -60,157,000 |
| Sale Of Investment | 44,386,000 | 16,403,000 | 5,627,000 | 31,601,000 | 59,384,000 |
| Investing Cash Flow | $-142,545,000 | $-94,342,000 | $-49,833,000 | $-37,601,000 | $-58,154,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 9,320,000 | 5,142,000 | 18,129,000 | 41,553,000 | 7,956,000 |
| Debt Issued | 15,673,000 | N/A | N/A | 21,166,000 | 19,003,000 |
| Debt Repayment | -6,906,000 | -11,894,000 | -8,331,000 | -9,447,000 | -12,915,000 |
| Common Stock Repurchased | N/A | N/A | N/A | -6,000,000 | 0 |
| Other Financing Activity | -8,426,000 | -5,060,000 | -25,677,000 | -37,554,000 | -7,753,000 |
| Financing Cash Flow | $9,661,000 | $-11,812,000 | $-15,879,000 | $9,718,000 | $6,291,000 |
| Exchange Rate Effect | 1,164,000 | -1,301,000 | 403,000 | -1,093,000 | -364,000 |
| Beginning Cash Position | 82,312,000 | 73,890,000 | 54,253,000 | 36,477,000 | 42,377,000 |
| End Cash Position | 90,106,000 | 82,312,000 | 73,890,000 | 54,253,000 | 36,477,000 |
| Net Cash Flow | $7,794,000 | $8,422,000 | $19,637,000 | $17,776,000 | $-5,900,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 139,514,000 | 115,877,000 | 84,946,000 | 46,752,000 | 46,327,000 |
| Capital Expenditure | -131,819,000 | -82,999,000 | -52,729,000 | -63,645,000 | -61,053,000 |
| Free Cash Flow | 7,695,000 | 32,878,000 | 32,217,000 | -16,893,000 | -14,726,000 |
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 77,670,000 | 56,478,000 | 35,291,000 | 17,127,000 | 59,248,000 |
| Depreciation Amortization | 65,756,000 | 46,285,000 | 29,489,000 | 14,262,000 | 52,795,000 |
| Income taxes - deferred | 11,470,000 | 10,648,000 | 518,000 | 507,000 | -4,648,000 |
| Accounts receivable | -7,333,000 | -1,855,000 | 122,000 | 1,247,000 | -3,249,000 |
| Accounts payable and accrued liabilities | 11,231,000 | 166,000 | -1,985,000 | -9,043,000 | 2,972,000 |
| Other Working Capital | -19,969,000 | -29,239,000 | -21,916,000 | -15,753,000 | -15,541,000 |
| Other Operating Activity | 689,000 | 2,572,000 | 8,011,000 | 8,668,000 | 24,300,000 |
| Operating Cash Flow | $139,514,000 | $85,055,000 | $49,530,000 | $17,015,000 | $115,877,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -128,320,000 | -89,851,000 | -55,623,000 | -24,255,000 | -77,658,000 |
| Net Acquisitions | -3,841,000 | -2,438,000 | -1,652,000 | 48,000 | -7,082,000 |
| Purchase Of Investment | -54,770,000 | -38,556,000 | -31,130,000 | -13,333,000 | -26,005,000 |
| Sale Of Investment | 44,386,000 | 35,545,000 | 19,178,000 | 7,737,000 | 16,403,000 |
| Investing Cash Flow | $-142,545,000 | $-95,300,000 | $-69,227,000 | $-29,803,000 | $-94,342,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 9,320,000 | 7,131,000 | 3,908,000 | 1,815,000 | 5,142,000 |
| Debt Issued | 15,673,000 | 746,000 | 746,000 | 746,000 | N/A |
| Debt Repayment | -6,906,000 | -5,207,000 | -3,766,000 | -526,000 | -11,894,000 |
| Other Financing Activity | -8,426,000 | -5,300,000 | -3,474,000 | -2,082,000 | -5,060,000 |
| Financing Cash Flow | $9,661,000 | $-2,630,000 | $-2,586,000 | $-47,000 | $-11,812,000 |
| Exchange Rate Effect | 1,164,000 | 1,027,000 | 1,424,000 | 416,000 | -1,301,000 |
| Beginning Cash Position | 82,312,000 | 82,312,000 | 82,312,000 | 82,312,000 | 73,890,000 |
| End Cash Position | 90,106,000 | 70,464,000 | 61,453,000 | 69,893,000 | 82,312,000 |
| Net Cash Flow | $7,794,000 | $-11,848,000 | $-20,859,000 | $-12,419,000 | $8,422,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 139,514,000 | 85,055,000 | 49,530,000 | 17,015,000 | 115,877,000 |
| Capital Expenditure | -131,819,000 | -92,297,000 | -57,202,000 | -25,019,000 | -82,999,000 |
| Free Cash Flow | 7,695,000 | -7,242,000 | -7,672,000 | -8,004,000 | 32,878,000 |
Research
Biotechnology, Clinical Trials, FDA, IND,
Biotechnology, Clinical Trials, Industry, Trending,
Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Mar 2026) | Next Qtr. (Jun 2026) | Current Year (2026) | Next Year (2027) |
|---|---|---|---|---|
| No. of Analysts | 45 | 43 | 60 | 55 |
| Avg. Estimate | 1.65 | 1.79 | 7.77 | 9.47 |
| Low Estimate | 1.38 | 1.5 | 6.47 | 7.68 |
| High Estimate | 2.75 | 2.18 | 9.65 | 14.21 |
| Year Ago EPS | 1.59 | 1.68 | 7.17 | 7.77 |
Revenue Estimate
Currency in USD | Current Qtr. (Mar 2026) | Next Qtr. (Jun 2026) | Current Year (2026) | Next Year (2027) |
|---|---|---|---|---|
| No. of Analysts | 47 | 44 | 59 | 59 |
| Avg. Estimate | 177.07B | 188.56B | 807.68B | 901.55B |
| Low Estimate | 172.88B | 183.01B | 788.35B | 839.8B |
| High Estimate | 179.89B | 198.16B | 890B | 955.41B |
| Year Ago Sales | 155.67B | 167.7B | 716.92B | 807.68B |
| Sales Growth (year/est) | 13.75% | 12.43% | 12.66% | 11.62% |
Earnings History
Currency in USD | 3/31/2025 | 6/30/2025 | 9/30/2025 | 12/31/2025 |
|---|---|---|---|---|
| EPS Est. | 1.36 | 1.33 | 1.56 | 1.96 |
| EPS Actual | 1.59 | 1.68 | 1.95 | 1.95 |
| Difference | 0.23 | 0.35 | 0.39 | -0.01 |
| Surprise % | 17.08% | 26.13% | 25.20% | -0.49% |
EPS Trend
Currency in USD | Current Qtr. (Mar 2026) | Next Qtr. (Jun 2026) | Current Year (2026) | Next Year (2027) |
|---|---|---|---|---|
| Current Estimate | 1.65 | 1.79 | 7.77 | 9.47 |
| 7 Days Ago | 1.65 | 1.79 | 7.76 | 9.46 |
| 30 Days Ago | 1.64 | 1.79 | 7.75 | 9.43 |
| 60 Days Ago | 1.72 | 1.84 | 7.85 | 9.54 |
| 90 Days Ago | 1.72 | 1.84 | 7.82 | 9.51 |
EPS Revisions
Currency in USD | Current Qtr. (Mar 2026) | Next Qtr. (Jun 2026) | Current Year (2026) | Next Year (2027) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 3 |
| Up Last 30 Days | 2 | 1 | 2 | 4 |
| Down Last 7 Days | 1 | 3 | 3 | 1 |
| Down Last 30 Days | 3 | 5 | 6 | 4 |
Growth Estimates
| Symbol | Current Qtr. | Next Qtr. | Current Year | Next Year |
|---|---|---|---|---|
| AMZN | 3.16% | 5.90% | 8.03% | 21.27% |
| S&P 500 | 12.32% | 18.12% | 17.35% | 16.67% |
Equity Analyst
Milo Bussell
Analyst, Consumer and TMT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jeffrey P. Bezos | Founder & Executive Chairman | 1.68M | -- | 1964 |
| Mr. Andrew R. Jassy | President, CEO & Director | 1.6M | -- | 1968 |
| Mr. Brian T. Olsavsky | Senior VP & CFO | 371.9k | -- | 1964 |
| Mr. David A. Zapolsky J.D. | Senior VP and Chief Global Affairs & Legal Officer | 371.9k | -- | 1964 |
| Mr. Douglas J. Herrington | Chief Executive Officer of Worldwide Amazon Stores | 386.44k | -- | 1967 |
| Mr. Matthew S. Garman | Chief Executive Officer of Amazon Web Series | 384.27k | -- | 1977 |
| Ms. Shelley L. Reynolds | VP, Worldwide Controller & Principal Accounting Officer | 163.2k | -- | 1965 |
| Dr. Werner Vogels | Chief Technology Officer | -- | -- | -- |
| Mr. Dave Fildes | Vice President of Investor Relations | -- | -- | -- |
| Drew Herdener | Senior Vice President of Communications & Corporate Responsibility | -- | -- | -- |
Amazon.com, Inc.
- Sector:
- Consumer Cyclical
- Industry: Internet Retail
- Full Time Employees:
- 1,576,000
We are looking for talented interns to learn and help investors find valuable companies.